FTC Wants To Keep Fighting Opana Pay-For-Delay Deal
The Federal Trade Commission has sought to revive allegations of a pay-for-delay scheme between Endo Pharmaceuticals and generic-drug maker Impax to stall the launch of a generic for opioid medication Opana...To view the full article, register now.
Already a subscriber? Click here to view full article